Attached files

file filename
EX-32.2 - EXHIBIT 32.2 - BIO-TECHNE Corpex_187168.htm
EX-32.1 - EXHIBIT 32.1 - BIO-TECHNE Corpex_187167.htm
EX-31.2 - EXHIBIT 31.2 - BIO-TECHNE Corpex_187166.htm
EX-31.1 - EXHIBIT 31.1 - BIO-TECHNE Corpex_187165.htm
EX-21 - EXHIBIT 21 - BIO-TECHNE Corpex_187163.htm
EX-10.11 - EXHIBIT 10.11 - BIO-TECHNE Corpex_200249.htm
EX-10.10 - EXHIBIT 10.10 - BIO-TECHNE Corpex_200248.htm
EX-10.9 - EXHIBIT 10.9 - BIO-TECHNE Corpex_200247.htm
EX-10.8 - EXHIBIT 10.8 - BIO-TECHNE Corpex_200246.htm
EX-10.7 - EXHIBIT 10.7 - BIO-TECHNE Corpex_200245.htm
EX-10.6 - EXHIBIT 10.6 - BIO-TECHNE Corpex_200244.htm
EX-10.5 - EXHIBIT 10.5 - BIO-TECHNE Corpex_200243.htm
EX-10.4 - EXHIBIT 10.4 - BIO-TECHNE Corpex_200242.htm
EX-10.3 - EXHIBIT 10.3 - BIO-TECHNE Corpex_200241.htm
EX-4.1 - EXHIBIT 4.1 - BIO-TECHNE Corpex_201045.htm
10-K - FORM 10-K - BIO-TECHNE Corptech20200630_10k.htm

Exhibit 23

 

Consent of Independent Registered Public Accounting Firm

 

The Board of Directors
Bio-Techne Corporation:

 

We consent to the incorporation by reference in the registration statements (Nos. 333-37263, 333-88885, 333-49962, 333-170576, 333-199847, 333-207710, and 333-221143) on Form S-8 of Bio-Techne Corporation of our reports dated August 26, 2020, with respect to the consolidated balance sheets of Bio-Techne Corporation as of June 30, 2020 and 2019, the related consolidated statements of earnings and comprehensive income, shareholders’ equity, and cash flows for each of the years in the three-year period ended June 30, 2020, and the related notes (collectively, “the consolidated financial statements”), and the effectiveness of internal control over financial reporting as of June 30, 2020 which reports appear in the June 30, 2020 annual report on Form 10-K of Bio-Techne Corporation.

 

Our report refers to changes in the methods of accounting for revenue and leases.

 

/s/ KPMG LLP

 

Minneapolis, Minnesota

August 26, 2020